Novogene. 

Novogene Co., Ltd. is a global provider of comprehensive genomic services and advanced solutions. Its offerings span a wide array of genomic applications, including human, animal, plant, and microbial genome sequencing, alongside gene regulation and single-cell sequencing technologies. The company also specializes in cancer genomic profiling, whole exome sequencing (including clinical-grade versions), and FFPE RNA sequencing. Furthermore, Novogene develops proprietary tools such as NovoFocus, a next-generation sequencing (NGS)-based companion diagnostic for PARP inhibitor treatments, and NovoNeoantigen, a bioinformatics pipeline that identifies cancer neoantigens by analyzing whole exome and whole transcriptome sequencing data from matched tumor and normal samples. In a strategic collaboration, Novogene partners with Hummingbird Bioscience Pte. Ltd. to aid in the advancement of HMBD-001. This investigational anti-HER3 antibody is being assessed for its potential to treat diverse cancer types, notably those driven by NRG1-fusion. Established in 2011, Novogene Co., Ltd. operates from its headquarters in Beijing, China.